Medication info
Lanstop Capsule 30 mg (Lansoprazole Granules)

Lanstop Capsule 30 mg (Lansoprazole Granules)

Prescription medicationHard capsuleOral
Ingredient · strength
Lansoprazole Granules›353mg / 1 capsule
Manufacturer / importer
Korea PMG Pharmaceutical Co., Ltd.
Appearance
A white to light brown granule-filled hard capsule with a white upper and lower body.
Packaging
28 capsules per bottle
Approval status
Active

MFDS item code 201306401 · Approved 2013.03.22 · Insurance code 697100460

Summary

Main use
Treatment and prevention of gastric and duodenal ulcers, Helicobacter pylori infection, gastroesophageal reflux disease, and gastric acid hypersecretion
Who takes it
Adults · Children
Adult dose
This medicine should be taken before meals. For patients who have difficulty swallowing the medicine, open the capsule, mix the contents with a small amount (60 mL) of orange juice or tomato juice, and administer immediately. To ensure the full dose is taken, rinse the glass with twice the amount of juice or more and drink immediately. After opening the capsule, do not chew or crush the medicine before taking it. Short-term treatment of active duodenal ulcers: Administer lansoprazole 15 mg orally once daily for 4 weeks. Short-term treatment of active benign gastric ulcers: Administer lansoprazole 30 mg orally once daily for 8 weeks. Eradication of Helicobacter pylori to reduce recurrence of duodenal ulcers Administer lansoprazole 30 mg with clarithromycin 250 ∼ 500 mg and amoxicillin 1,000 mg twice daily (every 12 hours) for 7 days. Treatment may be given for up to 14 days if needed. Administer lansoprazole 30 mg with amoxicillin 1,000 mg three times daily (every 8 hours) for 14 days. Maintenance therapy after treatment of duodenal ulcers: Administer lansoprazole 15 mg orally once daily. The duration of the controlled clinical trial did not exceed 12 months. Treatment of NSAID-associated gastric ulcers: Administer lansoprazole 30 mg orally once daily for 8 weeks. The duration of the controlled clinical trial did not exceed 8 weeks. Reduction of the risk of NSAID-associated gastric ulcers: Administer lansoprazole 15 mg orally once daily for 12 weeks. The duration of the controlled clinical trial did not exceed 12 weeks. Short-term treatment of symptoms associated with gastroesophageal reflux disease Administer lansoprazole 15 mg orally once daily for 8 weeks. Short-term treatment of erosive reflux esophagitis: Administer lansoprazole 30 mg orally once daily for 8 weeks. Maintenance therapy after treatment of erosive reflux esophagitis: Administer lansoprazole 15 mg orally once daily. Pathological hypersecretory conditions, including Zollinger-Ellison syndrome The dosage of lansoprazole for pathological hypersecretory conditions varies for each patient. Treatment in adults is usually started at 60 mg once daily. The dose should be adjusted according to the patient's needs and may be continued for as long as it is clinically effective. Doses of 90 mg twice daily have been administered. If the daily dose exceeds 120 mg, it should be given in divided doses. Because clearance of this medicine is reduced in elderly patients, dose adjustment is necessary. Do not exceed a daily dose of 30 mg. In patients with hepatic impairment, metabolism and excretion of this medicine may be delayed; administer cautiously, including consideration of dose adjustment.
Child dose
Pediatric and adolescent patients aged 12 ∼ 17 years — Short-term treatment of symptoms associated with non-erosive gastroesophageal reflux disease: 15 mg once daily for 8 weeks Pediatric and adolescent patients aged 12 ∼ 17 years — Short-term treatment of erosive reflux esophagitis: 30 mg once daily for 8 weeks Pediatric patients aged 1 ∼ 11 years, weighing 30 kg or less: 15 mg once daily for 12 weeks Pediatric patients aged 1 ∼ 11 years, weighing more than 30 kg: 30 mg once daily for 12 weeks

Ingredients

Manufacturer
Korea PMG Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment and prevention of gastric and duodenal ulcers, Helicobacter pylori infection, gastroesophageal reflux disease, and gastric acid hypersecretion

  • Active duodenal ulcers
  • active benign gastric ulcers
  • duodenal ulcers
  • NSAID-induced gastric ulcers
  • symptoms related to gastroesophageal reflux disease
  • erosive esophagitis
  • Zollinger-Ellison syndrome
  • pathological hypersecretion conditions.
View approved original text

This medication is effective for the short-term treatment of active duodenal ulcers and gastric ulcers. It is also used to eradicate Helicobacter pylori infection to prevent the recurrence of duodenal ulcers. Additionally, it helps in the treatment of gastric ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs) and reduces the associated risk. It can be used not only for the short-term treatment of gastroesophageal reflux disease and erosive esophagitis but also as maintenance therapy after treatment. Furthermore, it is applicable for the treatment of conditions involving excessive gastric acid secretion, such as Zollinger-Ellison syndrome. This medication assists in the treatment and management of various gastrointestinal-related illnesses.

How to take

Adult dose

This medicine should be taken before meals. For patients who have difficulty swallowing the medicine, open the capsule, mix the contents with a small amount (60 mL) of orange juice or tomato juice, and administer immediately. To ensure the full dose is taken, rinse the glass with twice the amount of juice or more and drink immediately. After opening the capsule, do not chew or crush the medicine before taking it. Short-term treatment of active duodenal ulcers: Administer lansoprazole 15 mg orally once daily for 4 weeks. Short-term treatment of active benign gastric ulcers: Administer lansoprazole 30 mg orally once daily for 8 weeks. Eradication of Helicobacter pylori to reduce recurrence of duodenal ulcers Administer lansoprazole 30 mg with clarithromycin 250 ∼ 500 mg and amoxicillin 1,000 mg twice daily (every 12 hours) for 7 days. Treatment may be given for up to 14 days if needed. Administer lansoprazole 30 mg with amoxicillin 1,000 mg three times daily (every 8 hours) for 14 days. Maintenance therapy after treatment of duodenal ulcers: Administer lansoprazole 15 mg orally once daily. The duration of the controlled clinical trial did not exceed 12 months. Treatment of NSAID-associated gastric ulcers: Administer lansoprazole 30 mg orally once daily for 8 weeks. The duration of the controlled clinical trial did not exceed 8 weeks. Reduction of the risk of NSAID-associated gastric ulcers: Administer lansoprazole 15 mg orally once daily for 12 weeks. The duration of the controlled clinical trial did not exceed 12 weeks. Short-term treatment of symptoms associated with gastroesophageal reflux disease Administer lansoprazole 15 mg orally once daily for 8 weeks. Short-term treatment of erosive reflux esophagitis: Administer lansoprazole 30 mg orally once daily for 8 weeks. Maintenance therapy after treatment of erosive reflux esophagitis: Administer lansoprazole 15 mg orally once daily. Pathological hypersecretory conditions, including Zollinger-Ellison syndrome The dosage of lansoprazole for pathological hypersecretory conditions varies for each patient. Treatment in adults is usually started at 60 mg once daily. The dose should be adjusted according to the patient's needs and may be continued for as long as it is clinically effective. Doses of 90 mg twice daily have been administered. If the daily dose exceeds 120 mg, it should be given in divided doses. Because clearance of this medicine is reduced in elderly patients, dose adjustment is necessary. Do not exceed a daily dose of 30 mg. In patients with hepatic impairment, metabolism and excretion of this medicine may be delayed; administer cautiously, including consideration of dose adjustment.

Child dose

Pediatric and adolescent patients aged 12 ∼ 17 years — Short-term treatment of symptoms associated with non-erosive gastroesophageal reflux disease: 15 mg once daily for 8 weeks Pediatric and adolescent patients aged 12 ∼ 17 years — Short-term treatment of erosive reflux esophagitis: 30 mg once daily for 8 weeks Pediatric patients aged 1 ∼ 11 years, weighing 30 kg or less: 15 mg once daily for 12 weeks Pediatric patients aged 1 ∼ 11 years, weighing more than 30 kg: 30 mg once daily for 12 weeks

Precautions

This medication should not be used by patients with hypersensitivity to specific ingredients or to benzimidazole derivatives, or those who have experienced such reactions in the past. Caution is also advised when using in conjunction with penicillin antibiotics or macrolide antibiotics due to potential allergies. It is safest for pregnant or breastfeeding women to avoid this medication. Patients with lactose intolerance or certain genetic metabolic disorders should refrain from using this medication due to the lactose it contains. Caution should also be exercised in patients with impaired liver or kidney function, the elderly, children, and nursing mothers, and they should adhere closely to medical advice. Serious side effects such as anaphylaxis, blood disorders, liver function impairment, and skin reactions can infrequently occur, so immediate consultation with healthcare professionals is necessary if any unusual symptoms arise. Long-term use can lead to nutrient deficiencies such as vitamin B12 deficiency or hypomagnesemia, necessitating regular monitoring. This medication may interact with other drugs, so it’s important to inform healthcare providers of all medications being taken. In particular, caution is needed when used in combination with specific antiviral medications, antibiotics, anticoagulants, etc., as changes in drug concentration could reduce effectiveness or increase the risk of side effects. During treatment, if symptoms such as diarrhea, abdominal pain, rash, or shortness of breath occur, an immediate visit to a healthcare institution is warranted. Symptoms such as dizziness or drowsiness may occur, so caution should be exercised when driving or operating machinery. In cases of overdose, gastric lavage or symptom-specific treatment may be needed, and this medication is not removed by dialysis. Keep this medication out of the reach of children, and for quality maintenance, do not transfer to other containers.

Side effects

Anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, urticaria, generalized rash, facial swelling, dyspnea, shock, pancytopenia, agranulocytosis, hemolytic anemia, leukopenia, thrombocytopenia, anemia, jaundice, elevated AST, elevated ALT, toxic liver dysfunction, toxic epidermal necrolysis, Stevens-Johnson syndrome, DRESS syndrome, interstitial pneumonia, fever, cough, abnormal lung sounds, interstitial nephritis, acute renal failure, membranous colitis, rectal bleeding, abdominal pain, frequent diarrhea, headache, diarrhea, abdominal distension, allergic reactions, back pain, weakness, candidiasis, carcinoma, chills, chest pain, edema, fever, flu symptoms, halitosis, infection, malaise, neck stiffness, pelvic pain, angina, arrhythmia, bradycardia, tachycardia, cerebrovascular accident, cerebral infarction, hypertension, hypotension, migraine, myocardial infarction, palpitations, vasodilation, syncope, asthma, bronchitis, increased cough, epistaxis, hemoptysis, hiccups, pneumonia, upper respiratory tract infection, laryngeal neoplasm, pulmonary fibrosis, pharyngitis, pleural disorders, respiratory disorders, rhinitis, sinusitis, wheezing, acne, hair loss, pruritus, rash, contact dermatitis, dry skin, nail disorders, skin cancer, skin diseases, sweating, abnormal vision, amblyopia, blepharitis, cataract, conjunctivitis, dry eye, ear disorders, eye disorders, glaucoma, abnormal olfaction, photophobia, retinal degeneration, loss of taste, blurred vision, deafness, ocular pain, otitis media, distortion of taste, tinnitus, visual field constriction, urinary disorders, renal colic, penile disorders, testicular disorders, urethral pain, polyuria, frequency of urination, post-void residual urine, menstrual irregularities, chest tenderness, chest expansion, gynecomastia, diabetes, hematuria, erectile dysfunction, kidney stones, hepatic toxicity, pancreatitis, dysgeusia, aplastic anemia, leukopenia, thrombocytopenic purpura, eosinophilia, hypomagnesemia, Clostridium difficile-associated diarrhea, fracture, myositis, erythema multiforme, acute generalized pustular exanthem, speech disorders, urinary retention, increased AST, increased ALT, increased ALP, increased LDH, increased γ-GTP, weakness, hyponatremia, elevated total cholesterol, decreased total cholesterol, tongue paralysis, lip paralysis, limb paralysis, abdominal pain, fecal incontinence, abdominal bloating, nausea, vomiting, stomatitis, glossitis, thirst, heartburn, gastroesophageal reflux, decreased appetite, neutropenia, leukocytosis, thrombocytopenia, rash, itching, drowsiness, dizziness, insomnia, paralysis, depressive state, elevated triglycerides, increased uric acid, positive urine protein, positive urine glucose, malaise, elevated AST, elevated ALT, increased creatinine, increased globulin, abnormal WBC, abnormal AG ratio, abnormal RBC, hyperbilirubinemia, abnormal potassium levels in blood, increased urinary potassium, crystalluria, decreased hemoglobin, hyperlipidemia, electrolyte imbalance, cholesterol abnormalities, increased glucocorticoids, abnormal platelets, increased gastrin concentration, positive fecal occult blood test, albuminuria, diabetes, hematuria

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air and moisture. It is important to maintain storage temperatures between 1°C and 30°C at room temperature to ensure the medication's efficacy.

Appearance and packaging

Appearance

A white to light brown granule-filled hard capsule with a white upper and lower body.

Package unit

28 capsules per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.